A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Refractory Nephrotic Syndrome

NCT02257697 Phase 3 COMPLETED

To demonstrate that the treatment effect in refractory nephrotic syndrome of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.

Details

Lead sponsor	Asahi Kasei Therapeutics Corporation
Phase	Phase 3
Status	COMPLETED
Enrolment	239
Start date	2014-11
Completion	2018-11

Conditions

• Nephrotic Syndrome

Interventions

• Mizoribine (MZR)
• Cyclophosphamide (CTX)

Primary outcomes

• Total Remission rate — 52 weeks

Countries

China